Apotex Corp. Initiates Nationwide Recall of Lacosamide Oral Solution Due to Defective Container
Apotex Corp. has initiated a Class II recall for 20,648 bottles of Lacosamide Oral Solution, 10 mg/mL, distributed US Nationwide. The recall, D-0457-2025, stems from defective containers, specifically leaking units when stored horizontally. This event necessitates immediate action from procurement and regulatory teams to assess supply chain integrity and patient safety risks.
Apotex Corp. Initiates Nationwide Recall of Lacosamide Oral Solution Over Container Defect
Apotex Corp., based in Weston, FL, has initiated a Class II recall (D-0457-2025) for 20,648 bottles of its Lacosamide Oral Solution, USP, 10 mg/mL, 200 mL. This significant regulatory action, which commenced on May 28, 2025, targets Batch # TZ5589 with an expiration date of January 31, 2026. The primary reason for this recall is a defective container, specifically identified as a leaking unit when stored horizontally. For procurement directors and supply chain VPs, this event signals an immediate need to verify inventory of this specific batch across US nationwide distribution channels. A Class II classification indicates that the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This classification demands prompt attention to mitigate potential patient safety risks and ensure compliance with FDA regulations. The firm-initiated voluntary recall underscores Apotex Corp.'s responsibility to address product quality issues proactively, but the underlying manufacturing defect warrants thorough investigation by all stakeholders in the supply chain.
Manufacturing Origin and Supply Chain Implications for Lacosamide
The recalled Lacosamide Oral Solution, a critical anti-epileptic medication, is manufactured by Apotex Inc. in Toronto, Ontario, Canada M9L 1T9, for Apotex Corp. in Weston, FL 33326. This dual-entity structure means that procurement teams must consider quality oversight across international borders. The defect, a leaking container observed under horizontal storage conditions, highlights potential vulnerabilities in packaging integrity that could compromise product stability and efficacy. For regulatory affairs heads, this incident necessitates a review of quality agreements and manufacturing controls with Apotex Inc., particularly concerning packaging specifications and testing protocols. The distribution pattern is specified as US Nationwide, indicating broad market exposure and a substantial logistical challenge for recall execution. Supply chain VPs must assess the potential for stock-outs or delays in the availability of Lacosamide, a drug where consistent supply is paramount for patient care. Understanding the root cause of the container defect is crucial for preventing similar issues with other products sourced from Apotex Inc. or Apotex Corp., ensuring long-term supply chain resilience and product quality.
Regulatory Classification, Distribution Scope, and Ongoing Remediation Efforts
The FDA's classification of this event as a Class II recall for Lacosamide Oral Solution underscores the potential for adverse health consequences, albeit temporary or reversible. This classification mandates a robust response from Apotex Corp. and its distribution partners. The recall's status is currently 'Ongoing,' as reported on June 11, 2025, signifying that the firm's efforts to remove the affected product from the market are still in progress. For business development executives, this ongoing recall presents a potential reputational risk for Apotex Corp. and could influence future market perceptions of their product quality. The initial firm notification involved multiple channels, including email, fax, letter, press release, telephone, and direct visits, indicating a comprehensive approach to alert distributors and healthcare providers across the US. Procurement directors should immediately quarantine any affected batch (TZ5589) and await further instructions from Apotex Corp. regarding return or destruction. Furthermore, regulatory affairs teams should monitor the FDA's updates closely for any additional findings or enforcement actions that may arise from this defective container issue, which could impact other products or facilities associated with Apotex.